Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABFRA:3F80 65 9-Day RSI is 44.71 as of Jul. 19, 2026. GuruFocus rates FRA:3F80 with a GF Score™ of 65/100 and a GF Value™ of kr1.72. The stock has 3 warning signs investors should review. Among 867 Medical Devices & Instruments companies, Q-linea AB ranks worse than 58.36% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-19), Q-linea AB's 9-Day RSI is 44.71.
The industry rank for Q-linea AB's 9-Day RSI or its related term are showing as below:
FRA:3F80's 9-Day RSI is ranked worse than 58.36% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 45.51
vs FRA:3F80: 44.71
Q-linea AB (FRA:3F80) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Q-linea AB 9-Day RSI Related Terms
FRA:3F80 vs ABT, SYK, MDT: 9-Day RSI Comparison
For the Medical Devices subindustry, Q-linea AB's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Q-linea AB's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-linea AB (FRA:3F80) has a 9-Day RSI of 44.71 as of Jul. 19, 2026. According to the industry distribution chart, Q-linea AB ranks #506 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 58.4%.
Is Q-linea AB's 9-Day RSI too high?
Q-linea AB's current 9-Day RSI is 44.71. The Medical Devices & Instruments industry median 9-Day RSI is 45.51. Q-linea AB's value of 44.71 is 1.8% below this industry median. Based on the distribution chart, Q-linea AB ranks #506 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Q-linea AB has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's 9-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #506 out of 867 companies for 9-Day RSI. This places Q-linea AB in the lower half of its industry. The industry median 9-Day RSI is 45.51. Q-linea AB's value of 44.71 is 1.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 45.51, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-linea AB's current 9-Day RSI of 44.71 is 1.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 45.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current 9-Day RSI is 44.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (FRA:3F80) has a current 9-Day RSI of 44.71. The stock's GF Value™ is kr1.72, compared to a current price of kr1.49 — trading 13.4% below its estimated fair value. The current 9-Day RSI is 44.71 and 1.8% below the Medical Devices & Instruments industry median of 45.51. Q-linea AB's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Q-linea AB (FRA:3F80), the current 9-Day RSI is 44.71 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (FRA:3F80) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1.49 is trading 13.4% below its estimated GF Value™ of kr1.72.
Key valuation signals for FRA:3F80:
9-Day RSI: 44.71
GF Value™: kr1.72 vs. price of kr1.49 (13.4% below fair value)
Industry Position: 1.8% below the Medical Devices & Instruments median (#506 of 867)
No single metric tells the full story. See the FRA:3F80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
65GF Score
Get the complete analysis for FRA:3F80
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3F80 has been successfully added to your 
